EGFR over-expression has been linked to metastatic phenotypes and metastatic breast cancers are considered resistant to EGFR inhibitors, which have not been clinically effective at reducing metastasis or overall survival in breast cancer patients [1, 17]. The gene discussed is EGFR; the disease is breast carcinoma.